研究実績

Phase II study of capecitabine plus oxaliplatin in patients with gastric cancer resistant/intolerable to CDDP (OGSG1403)

Junji Kawata, Naotoshi Sugimoto, Hirokazu Taniguchi, Shugo Ueda, Kohei Murakami, Kazuhiro Nishikawa, Yukinori Kurokawa, Kazumasa Fujitani, Hisato Kawakami, Daisuke Sakai, Toshio Shimokawa, Taroh Satoh  Osaka Gastrointestinal Study Group (OGSG)  ESMO-GI 2019, Barcelona, Spain,3 – 6 July 2019

前の記事 次の記事 一覧ページへ戻る